



Ujagar S. Bhachu, PEng., CEng., Mechanical Engineer
Materials Safety and Inspection Branch,
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety And Safeguards.

24 November, 1999


Dear Mr. Bhachu,

Per our telephone conversation of November 23, 1999 the following is respectfully submitted:

Because of the small size of the sources, vials, and lead safe the requirements under 10 CFR 32.74 (a)(3) will be accomplished by providing in a brochure, with every shipment, the following statement:

"The US Nuclear Regulatory Commission has approved this sealed source (I-125 Brachytherapy Sources) for distribution to persons licensed to use byproduct material identified in paragraph 35.400 10 CFR part 35, to persons who hold an equivalent license issued by an Agreement State, and outside the United States to persons authorized by the appropriate authority."

Sincerely Yours,



Stanley L. Mills, Ph.D., R.Ph.
President and CEO
Mills Pharmaceuticals, Inc.
120 N.E. 26th Street
Oklahoma City, Oklahoma 73105
405-525-3141
405-525-3143 FAX

Cover Page

Xerox Document WorkCentre 450c

Nov-18-99

16:34

To:

Fax: 301 415 5369

From: M

Fax: 4055253143

Pages: 3 not including this page

MILLS BIOPHARMACEUTICALS INC.

120 N.E. 26th Street
Oklahoma City, OK 73105

Phone: (405) 525-3141

FAX: (405) 525-3143

FAX TRANSMITTAL

For your information,
no response necessary

Please respond/reply
as soon as possible

TO: Mr. Ujagar S. Bhachu Mail Stop - 8F27

COMPANY: U. S. Nuclear Regulatory Commission

FROM: Dr. Stanley L. Mills

DATE: 18 November 1999

This is a fax transmission consisting of 3 page(s). If all pages were not received or you received this fax in error please contact this office immediately.

MESSAGE: Please confirm receipt of this

fax.

Thank you
SLM